You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Oncovex MGM-CSF –mediated regression of contralateral (non-injected) tumors in the A20 murine lymphoma model does not involve direct viral oncolysis

Article Text

Article menu

Download PDFPDF

Poster Presentation
Oncovex MGM-CSF –mediated regression of contralateral (non-injected) tumors in the A20 murine lymphoma model does not involve direct viral oncolysis
  1. Keegan Cooke1,
  2. James Rottman2,
  3. Jinghui Zhan1,
  4. Petia Mitchell1,
  5. Oluwatayo Ikotun1,
  6. Brittany Yerby1,
  7. Angela Chong3,
  8. Charles Glaus1,
  9. Achim K Moesta4 and
  10. Beltran Pedro5
  1. Aff1 grid.417886.40000000106575612Amgen Thousand Oaks CA USA
  2. Aff2 grid.417886.40000000106575612Amgen Boston MA USA
  3. Aff3 grid.417886.40000 0001 0657 5612Amgen San Francisco CA USA
  4. Aff4 grid.417886.40000000106575612Amgen Inc. South San Francisco CA USA
  5. Aff5 grid.417886.40000000106575612Amgen Inc. Thousand Oaks CA USA

https://doi.org/10.1186/2051-1426-3-S2-P336

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Talimogene laherparepvec (T-VEC) is an injectable modified oncolytic herpes simplex virus type-1 (HSV-1) hypothesized to be efficacious by at least two complimentary mechanisms of action: a) direct oncolysis of the injected tumor and b) elicitation of a systemic anti-tumor immune response against non-injected lesions and metastases. The purpose of this study was to test that hypothesis that direct viral oncolysis was not involved in the regression of contralateral (non-injected) tumors.

    Methods

    A20 cells (2x106) were injected subcutaneously on the right (injected) and left (contralateral) flank of female BALB/c mice. On day 10, mice were randomized into 4 groups based on tumor volume (~150 mm3, n=10/group). Tumor growth and body weight were measured twice per week throughout the experiment using calipers and an analytical scale, respectively. OncoVEXmGM-CSF (T-VEC with murine GM-CSF), 3x104-3x106PFU/mouse, was delivered intratumorally every 3 days during the first week. Viral detection was performed in injected and contralateral tumors after a single injection of OncoVEXmGM-CSF. Four approaches were used to detect the presence of virus in contralateral tumors and tissues: ddPCR (viral DNA), Fluidigm analysis (viral gene mRNA), immunohistochemistry (HSV-1 protein) and PET imaging with [18F]FHBG (active thymidine kinase).

    Results

    OncoVEXmGM-CSF treatment caused tumor regression and complete cures in 10/10 injected tumors and 5/10 contralateral tumors when dosed intratumorally at 3x106 PFU/mouse. Viral DNA was detected by ddPCR in all injected tumors, dose proportionally (4 mice per viral concentration, 5x103, 5x104, 5x105 and 5x106 PFU, total 16 mice). In contrast, viral DNA was only detected in 1/16 contralateral tumors (1 tumor in the 5x105 PFU group). The level of viral DNA in this contralateral tumor was 1:1000 that detected in injected tumors and equivalent to that found in the blood of one mouse in the 5x106 PFU group. HSV-1 viral gene expression analyzed by Fluidigm, viral capsid protein detected by immunohistochemistry, and HSV-1 thymidine kinase activity measured with [18F]FHBG PET were detected in all OncoVEXmGM-CSF injected tumors between 24-168 hours post-infection. In contrast, no HSV-1 mRNA, protein, or thymidine kinase activity could be detected in contralateral tumors up to 168 hours post infection.

    Conclusion

    The data presented here strongly suggests that direct viral oncolysis is not responsible for regression of contralateral tumors in the A20 murine lymphoma model. Detailed analysis of the adaptive immune response driven by OncoVEXmGM-CSF in contralateral A20 tumors is currently being studied.